Farmmi released FY2024 Q2 earnings on August 9 (EST), actual revenue 18.22 M USD, actual EPS 0.3 USD

Brief Summary

Farmmi reported Q2 2024 revenue of $18.22 million and EPS of $0.3, showing solid performance compared to its peers, many of whom reported negative earnings per share in their own Q2 results Seeking Alpha+ 8.

Impact of The News

Farmmi’s financial briefing indicates a positive performance with an EPS of $0.3, despite many peers in the industry reporting negative EPS for the same period, such as Dianthus Therapeutics (-$0.51), Disc Medicine (-$1.03), and Calumet (-$0.48) Seeking Alpha+ 3.

Comparison with Peers:

• Revenue: Farmmi’s revenue of $18.22 million positions it broadly within the lower bracket compared to larger firms like Calumet that reported $1.13 billion Seeking Alpha. However, this is significant for its niche sector.
• Earnings Per Share (EPS): Positive EPS contrasts with negative EPS reports from several peers, highlighting Farmmi’s stronger profitability despite challenging market conditions.

Impact and Business Trend:

• Market Expectations: The positive EPS suggests Farmmi may have exceeded market expectations, especially when compared to peers experiencing losses Seeking Alpha+ 2.
• Business Status and Future Trends: The solid performance may signal robust operational efficiency and potentially better market positioning, which could lead to increased investor confidence. Further growth could be anticipated if Farmmi capitalizes on its current profitability to expand operations or market reach.